The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
A groundbreaking discovery using artificial intelligence has identified a naturally occurring molecule, BRP, that targets the brain's appetite center, potentially offering a new and improved alternative for weight management compared to current GLP-1 medications.
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
The world of biohacking is increasingly embracing peptides, but what's the reality behind the hype? This article delves into the science, the risks of unregulated substances, and the potential impact of regulatory changes on access to these compounds.
While GLP-1 medications like Ozempic and Mounjaro offer significant weight loss potential, many individuals experience plateaus. Discover how a simple, affordable supplement – psyllium husk – can amplify their effects, improve satiety, and support long-term weight management.
While GLP-1 medications are celebrated for weight loss and reduced food noise, some users report emotional flattening. This article delves into the 'Ozempic personality' phenomenon, its potential causes, and expert perspectives on managing these psychological shifts.
As brand-name GLP-1 medications such as Ozempic and Wegovy become increasingly sought after for weight loss and diabetes management, many Canadians face significant cost barriers. The anticipation surrounding the approval of generic semaglutide offers a beacon of hope for improved accessibility and affordability. This article delves into the current landscape, patient stories, and expert insights on the journey towards more accessible peptide therapies.
Kaitlin Hicks, a former athlete, shares her powerful story of overcoming grief-induced weight gain, her health struggles, and her triumphant return to sport after losing a significant amount of weight.
New research suggests an outpatient endoscopic procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Wegovy and Mounjaro.
Country star Jelly Roll has shed an astonishing 275 pounds since 2022, transforming his life without relying on GLP-1 medications like Ozempic, Wegovy, or Mounjaro. His story highlights the power of addressing food addiction through therapy, consistent exercise, and mindful eating—proving that peptide therapy alternatives can yield profound, lasting change.
